Student or educator? Sign up with your school email and get 6 months of Pro free.
CoChat
Sign Up
Cited by 688

The DOI matches its Crossref record; 9 of the 9 references it cites were found in a registry or an index.

Durvalumab, with or without tremelimumab, plus platinum–etoposide versus platinum–etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial

Open access
Goldman, Jonathan W, Dvorkin, Mikhail, Chen, Yuanbin, Reinmuth, Niels, Hotta, Katsuyuki, Trukhin, Dmytro, Statsenko, Galina, Hochmair, Maximilian J, Özgüroğlu, Mustafa, Ji, Jun Ho, Garassino, Marina Chiara, Voitko, Oleksandr, Poltoratskiy, Artem, Ponce, Santiago, Verderame, Francesco, Havel, Libor, Bondarenko, Igor, Każarnowicz, Andrzej, Losonczy, György, Conev, Nikolay V, Armstrong, Jon, Byrne, Natalie, Thiyagarajah, Piruntha, Jiang, Haiyi, Paz-Ares, Luis, Dvorkin, Mikhail, Trukhin, Dmytro, Statsenko, Galina, Voitko, Nataliia, Poltoratskiy, Artem, Bondarenko, Igor, Chen, Yuanbin, Kazarnowicz, Andrzej, Paz-Ares, Luis, Özgüroglu, Mustafa, Conev, Nikolay, Hochmair, Maximilian, Burghuber, Otto, Havel, Libor, Çiçin, Irfan, Losonczy, György, Moiseenko, Vladimir, Erman, Mustafa, Kowalski, Dariusz, Wojtukiewicz, Marek, Adamchuk, Hryhoriy, Vasilyev, Alexander, Shevnia, Serhii, Valev, Spartak, Reinmuth, Niels, Ji, Jun Ho, Insa Molla, Maria Amelia, Ursol, Grygorii, Chiang, Anne, Hartl, Sylvia, Horváth, Zsolt, Pajkos, Gábor, Verderame, Francesco, Hotta, Katsuyuki, Kim, Sang-We, Smolin, Alexey, Göksel, Tuncay, Dakhil, Shaker, Roubec, Jaromir, Bogos, Krisztina, Garassino, Marina Chiara, Cornelissen, Robin, Lee, Jong-Seok, Garcia Campelo, Maria Rosario, Lopez Brea, Marta, Alacacioglu, Ahmet, Casarini, Ignacio, Ilieva, Rumyana, Tonev, Ivan, Somfay, Attila, Bar, Jair, Zer Kuch, Alona, Minelli, Mauro, Bartolucci, Roberta, Roila, Fausto, Saito, Haruhiro, Azuma, Koichi, Lee, Gyeong-Won, Luft, Alexander, Urda, Michal, Delgado Mingorance, Juan Ignacio, Majem Tarruella, Margarita, Spigel, David, Koynov, Krassimir, Zemanova, Milada, Panse, Jens, Schulz, Christian, Pápai Székely, Zsolt, Sárosi, Veronika, Delmonte, Angelo, Bettini, Anna Cecilia, Nishio, Makoto, Okamoto, Isamu, Hendriks, Lizza, Mandziuk, Slawomir, Lee, Yun Gyoo, Vladimirova, Lyubov, Isla Casado, Dolores, Domine Gomez, Manuel, Navarro Mendivil, Alejandro, Morán Bueno, Teresa, Wu, Shang-Yin, Knoble, Jeanna, Skrickova, Jana, Venkova, Violetka, Hilgers, Werner, Laack, Eckart, Bischoff, Helge, Fülöp, Andrea, Laczó, Ibolya, Kósa, Judit, Telekes, András, Yoshida, Tatsuya, Kanda, Shintaro, Hida, Toyoaki, Hayashi, Hidetoshi, Maeda, Tadashi, Kawamura, Tetsuji, Nakahara, Yasuharu, Claessens, Niels, Lee, Ki Hyeong, Chiu, Chao-Hua, Lin, Sheng-Hao, Li, Chien-Te, Demirkazik, Ahmet, Schaefer, Eric, Nikolinakos, Petros, Schneider, Jeffrey, Babu, Sunil, Lamprecht, Bernd, Studnicka, Michael, Fausto Nino Gorini, Carlos, Kultan, Juraj, Kolek, Vitezslav, Souquet, Pierre-Jean, Moro-Sibilot, Denis, Gottfried, Maya, Smit, Egbert, Lee, Kyung Hee, Kasan, Peter, Chovanec, Jozef, Goloborodko, Olexandr, Kolesnik, Oleksii, Ostapenko, Yuriy, Lakhanpal, Shailendra, Haque, Basir, Chua, Winston, Stilwill, Joseph, Sena, Susana Noemi, Girotto, Gustavo Colagiovanni, De Marchi, Pedro Rafael Martins, Martinelli de Oliveira, Fabricio Augusto, Dos Reis, Pedro, Krasteva, Rositsa, Zhao, Yanqiu, Chen, Chengshui, Koubkova, Leona, Robinet, Gilles, Chouaid, Christos, Grohe, Christian, Alt, Jürgen, Csánky, Eszter, Somogyiné Ezer, Éva, Heching, Norman Isaac, Kim, Young Hak, Aatagi, Shinji, Kuyama, Shoichi, Harada, Daijiro, Nogami, Naoyuki, Nokihara, Hiroshi, Goto, Hisatsugu, Staal van den Brekel, Agnes, Cho, Eun Kyung, Kim, Joo-Hang, Ganea, Doina, Ciuleanu, Tudor, Popova, Ekaterina, Sakaeva, Dina, Stresko, Marian, Demo, Pavol, Godal, Robert, Wei, Yu-Feng, Chen, Yen-Hsun, Hsia, Te-Chun, Lee, Kang-Yun, Chang, Huang-Chih, Wang, Chin-Chou, Dowlati, Afshin, Sumey, Christopher, Powell, Steven, Goldman, Jonathan, Zarba, Juan Jose, Batagelj, Emilio, Pastor, Andrea Viviana, Zukin, Mauro, Baldotto, Clarissa Serodio da Rocha, Schlittler, Luis Alberto, Calabrich, Aknar, Sette, Claudia, Dudov, Asen, Zhou, Caicun, Lena, Hervé, Lang, Susanne, Pápai, Zsuzsanna, Goto, Koichi, Umemura, Shigeki, Kanazawa, Kenya, Hara, Yu, Shinoda, Masahiro, Morise, Masahiro, Hiltermann, Jeroen, Mróz, Robert, Ungureanu, Andrei, Andrasina, Igor, Chang, Gee-Chen, Vynnychenko, Ihor, Shparyk, Yaroslav, Kryzhanivska, Anna, Ross, Helen, Mi, Kailhong, Jamil, Rodney, Williamson, Michael, Spahr, Joseph, Han, Zhigang, Wang, Mengzhao, Yang, Zhixiong, Hu, Jie, Li, Wei, Zhao, Jun, Feng, Jifeng, Ma, Shenglin, Zhou, Xiangdong, Liang, Zongan, Hu, Yi, Chen, Yuan, Bi, Minghong, Shu, Yongqian, Nan, Kejun, Zhou, Jianying, Zhang, Wei, Ma, Rui, Yang, Nong, Lin, Zhong, Wu, Gang, Fang, Jian, Zhang, Helong, Wang, Kai, Chen, Zhendong·2021·The Lancet Oncology
DOI 10.1016/s1470-2045(20)30539-8
Open this paper in CoChat — free account

Abstract

BACKGROUND First-line durvalumab plus etoposide with either cisplatin or carboplatin (platinum-etoposide) showed a significant improvement in overall survival versus platinum-etoposide alone in patients with extensive-stage small-cell lung cancer (ES-SCLC) in the CASPIAN study. Here we report updated results, including the primary analysis for overall survival with durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide alone. METHODS CASPIAN is an ongoing, open-label, sponsor-blind, randomised, controlled phase 3 trial at 209 cancer treatment centres in 23 countries worldwide. Eligible patients were aged 18 years or older (20 years in Japan) and had treatment-naive, histologically or cytologically documented ES-SCLC, with a WHO performance status of 0 or 1. Patients were randomly assigned (1:1:1) in blocks of six, stratified by planned platinum, using an interactive voice-response or web-response system to receive intravenous durvalumab plus tremelimumab plus platinum-etoposide, durvalumab plus platinum-etoposide, or platinum-etoposide alone. In all groups, patients received etoposide 80-100 mg/m2 on days 1-3 of each cycle with investigator's choice of either carboplatin area under the curve 5-6 mg/mL/min or cisplatin 75-80 mg/m2 on day 1 of each cycle. Patients in the platinum-etoposide group received up to six cycles of platinum-etoposide every 3 weeks and optional prophylactic cranial irradiation (investigator's discretion). Patients in the immunotherapy groups received four cycles of platinum-etoposide plus durvalumab 1500 mg with or without tremelimumab 75 mg every 3 weeks followed by maintenance durvalumab 1500 mg every 4 weeks. The two primary endpoints were overall survival for durvalumab plus platinum-etoposide versus platinum-etoposide and for durvalumab plus tremelimumab plus platinum-etoposide versus platinum-etoposide in the intention-to-treat population. Safety was assessed in all patients who received at least one dose of study treatment. This study is registered at ClinicalTrials.gov, NCT03043872. FINDINGS Between March 27, 2017, and May 29, 2018, 972 patients were screened and 805 were randomly assigned (268 to durvalumab plus tremelimumab plus platinum-etoposide, 268 to durvalumab plus platinum-etoposide, and 269 to platinum-etoposide). As of Jan 27, 2020, the median follow-up was 25·1 months (IQR 22·3-27·9). Durvalumab plus tremelimumab plus platinum-etoposide was not associated with a significant improvement in overall survival versus platinum-etoposide (hazard ratio [HR] 0·82 [95% CI 0·68-1·00]; p=0·045); median overall survival was 10·4 months (95% CI 9·6-12·0) versus 10·5 months (9·3-11·2). Durvalumab plus platinum-etoposide showed sustained improvement in overall survival versus platinum-etoposide (HR 0·75 [95% CI 0·62-0·91]; nominal p=0·0032); median overall survival was 12·9 months (95% CI 11·3-14·7) versus 10·5 months (9·3-11·2). The most common any-cause grade 3 or worse adverse events were neutropenia (85 [32%] of 266 patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 64 [24%] of 265 patients in the durvalumab plus platinum-etoposide group, and 88 [33%] of 266 patients in the platinum-etoposide group) and anaemia (34 [13%], 24 [9%], and 48 [18%]). Any-cause serious adverse events were reported in 121 (45%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group, 85 (32%) in the durvalumab plus platinum-etoposide group, and 97 (36%) in the platinum-etoposide group. Treatment-related deaths occurred in 12 (5%) patients in the durvalumab plus tremelimumab plus platinum-etoposide group (death, febrile neutropenia, and pulmonary embolism [n=2 each]; enterocolitis, general physical health deterioration and multiple organ dysfunction syndrome, pneumonia, pneumonitis and hepatitis, respiratory failure, and sudden death [n=1 each]), six (2%) patients in the durvalumab plus platinum-etoposide group (cardiac arrest, dehydration, hepatotoxicity, interstitial lung disease, pancytopenia, and sepsis [n=1 each]), and two (1%) in the platinum-etoposide group (pancytopenia and thrombocytopenia [n=1 each]). INTERPRETATION First-line durvalumab plus platinum-etoposide showed sustained overall survival improvement versus platinum-etoposide but the addition of tremelimumab to durvalumab plus platinum-etoposide did not significantly improve outcomes versus platinum-etoposide. These results support the use of durvalumab plus platinum-etoposide as a new standard of care for the first-line treatment of ES-SCLC. FUNDING AstraZeneca.

Overview

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1016/s1470-2045(20)30539-8

Cites

9 of 9 references verified0 citation errors · 0 not checkable

Statistics

Verification

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Citations

Cites

Show all 9 references

Cited by

Metadata

Authors
Goldman, J. W., Dvorkin, M., Chen, Y., Reinmuth, N., Hotta, K., Trukhin, D., Statsenko, G., Hochmair, M. J., Özgüroğlu, M., Ji, J. H., Garassino, M. C., Voitko, O., Poltoratskiy, A., Ponce, S., Verderame, F., Havel, L., Bondarenko, I., Każarnowicz, A., Losonczy, G., Conev, N. V., Armstrong, J., Byrne, N., Thiyagarajah, P., Jiang, H., Paz-Ares, L., Dvorkin, M., Trukhin, D., Statsenko, G., Voitko, N., Poltoratskiy, A., Bondarenko, I., Chen, Y., Kazarnowicz, A., Paz-Ares, L., Özgüroglu, M., Conev, N., Hochmair, M., Burghuber, O., Havel, L., Çiçin, I., Losonczy, G., Moiseenko, V., Erman, M., Kowalski, D., Wojtukiewicz, M., Adamchuk, H., Vasilyev, A., Shevnia, S., Valev, S., Reinmuth, N., Ji, J. H., Insa Molla, M. A., Ursol, G., Chiang, A., Hartl, S., Horváth, Z., Pajkos, G., Verderame, F., Hotta, K., Kim, S.-W., Smolin, A., Göksel, T., Dakhil, S., Roubec, J., Bogos, K., Garassino, M. C., Cornelissen, R., Lee, J.-S., Garcia Campelo, M. R., Lopez Brea, M., Alacacioglu, A., Casarini, I., Ilieva, R., Tonev, I., Somfay, A., Bar, J., Zer Kuch, A., Minelli, M., Bartolucci, R., Roila, F., Saito, H., Azuma, K., Lee, G.-W., Luft, A., Urda, M., Delgado Mingorance, J. I., Majem Tarruella, M., Spigel, D., Koynov, K., Zemanova, M., Panse, J., Schulz, C., Pápai Székely, Z., Sárosi, V., Delmonte, A., Bettini, A. C., Nishio, M., Okamoto, I., Hendriks, L., Mandziuk, S., Lee, Y. G., Vladimirova, L., Isla Casado, D., Domine Gomez, M., Navarro Mendivil, A., Morán Bueno, T., Wu, S.-Y., Knoble, J., Skrickova, J., Venkova, V., Hilgers, W., Laack, E., Bischoff, H., Fülöp, A., Laczó, I., Kósa, J., Telekes, A., Yoshida, T., Kanda, S., Hida, T., Hayashi, H., Maeda, T., Kawamura, T., Nakahara, Y., Claessens, N., Lee, K. H., Chiu, C.-H., Lin, S.-H., Li, C.-T., Demirkazik, A., Schaefer, E., Nikolinakos, P., Schneider, J., Babu, S., Lamprecht, B., Studnicka, M., Fausto Nino Gorini, C., Kultan, J., Kolek, V., Souquet, P.-J., Moro-Sibilot, D., Gottfried, M., Smit, E., Lee, K. H., Kasan, P., Chovanec, J., Goloborodko, O., Kolesnik, O., Ostapenko, Y., Lakhanpal, S., Haque, B., Chua, W., Stilwill, J., Sena, S. N., Girotto, G. C., De Marchi, P. R. M., Martinelli de Oliveira, F. A., Dos Reis, P., Krasteva, R., Zhao, Y., Chen, C., Koubkova, L., Robinet, G., Chouaid, C., Grohe, C., Alt, J., Csánky, E., Somogyiné Ezer, É., Heching, N. I., Kim, Y. H., Aatagi, S., Kuyama, S., Harada, D., Nogami, N., Nokihara, H., Goto, H., Staal van den Brekel, A., Cho, E. K., Kim, J.-H., Ganea, D., Ciuleanu, T., Popova, E., Sakaeva, D., Stresko, M., Demo, P., Godal, R., Wei, Y.-F., Chen, Y.-H., Hsia, T.-C., Lee, K.-Y., Chang, H.-C., Wang, C.-C., Dowlati, A., Sumey, C., Powell, S., Goldman, J., Zarba, J. J., Batagelj, E., Pastor, A. V., Zukin, M., Baldotto, C. S. D. R., Schlittler, L. A., Calabrich, A., Sette, C., Dudov, A., Zhou, C., Lena, H., Lang, S., Pápai, Z., Goto, K., Umemura, S., Kanazawa, K., Hara, Y., Shinoda, M., Morise, M., Hiltermann, J., Mróz, R., Ungureanu, A., Andrasina, I., Chang, G.-C., Vynnychenko, I., Shparyk, Y., Kryzhanivska, A., Ross, H., Mi, K., Jamil, R., Williamson, M., Spahr, J., Han, Z., Wang, M., Yang, Z., Hu, J., Li, W., Zhao, J., Feng, J., Ma, S., Zhou, X., Liang, Z., Hu, Y., Chen, Y., Bi, M., Shu, Y., Nan, K., Zhou, J., Zhang, W., Ma, R., Yang, N., Lin, Z., Wu, G., Fang, J., Zhang, H., Wang, K., & Chen, Z.
Venue
The Lancet Oncology
Publisher
Elsevier BV
Published
2021-01
Volume
22
Issue
1
Pages
51-65
ISSN
1470-2045 (ISSN-L)
DOI
10.1016/s1470-2045(20)30539-8
OpenAlex
W3110002524
Cited by
688
References
9
FWCI
27.59
Type
journal article
Language
en
Open access
green

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review

Data sources

Bibliographic data: Semantic Scholar, OpenAlex, Crossref.

Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).

Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.